Condition: Retinal Degeneration · Age-Related Macular Degeneration · Retinitis Pigmentosa · Sponsor: Food and Drug Administration (FDA)
The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.
This description comes directly from the study's public registry record.
Daniel X Hammer, Ph.D. · 301-796-9320 · daniel.hammer@fda.hhs.gov
Zhuolin Liu, Ph.D. · 301-796-7914 · zhuolin.liu@fda.hhs.gov
Always discuss trial participation with your own doctor first.
| NIH Clinical Center | Bethesda, Maryland, United States | Recruiting |
| Food and Drug Administration | Silver Spring, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05355415